These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12940460

  • 1. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene.
    Honda S, Tanaka-Kosugi C, Yamada S, Sano T, Matsumoto T, Itakura M, Yoshimoto K.
    Endocr J; 2003 Jun; 50(3):309-18. PubMed ID: 12940460
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
    Kirsch M, Mörz M, Pinzer T, Schackert HK, Schackert G.
    Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
    Vax VV, Bibi R, Diaz-Cano S, Gueorguiev M, Kola B, Borboli N, Bressac-de Paillerets B, Walker GJ, Dedov II, Grossman AB, Korbonits M.
    J Endocrinol; 2003 Aug; 178(2):301-10. PubMed ID: 12904177
    [Abstract] [Full Text] [Related]

  • 7. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus.
    Zhu J, Leon SP, Beggs AH, Busque L, Gilliland DG, Black PM.
    J Clin Endocrinol Metab; 1994 Apr; 78(4):922-7. PubMed ID: 8157722
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of molecular genetic changes in sporadic invasive pituitary adenomas.
    Nam DH, Song SY, Park K, Kim MH, Suh YL, Lee JI, Kim JS, Hong SC, Shin HJ, Park K, Eoh W, Kim JH.
    Exp Mol Med; 2001 Sep 30; 33(3):111-6. PubMed ID: 11642545
    [Abstract] [Full Text] [Related]

  • 9. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
    Møller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, Skjødt K, Pedersen NT.
    Leukemia; 2000 May 30; 14(5):898-904. PubMed ID: 10803523
    [Abstract] [Full Text] [Related]

  • 10. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.
    Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T, Komine C, Yokoyama T, Fukushima T.
    J Neurooncol; 2007 Jun 30; 83(2):153-62. PubMed ID: 17216555
    [Abstract] [Full Text] [Related]

  • 11. Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma.
    Choy KW, Pang CP, Yu CB, Wong HL, Ng JS, Fan DS, Lo KW, Chai JT, Wang J, Fu W, Lam DS.
    Hum Mutat; 2002 Nov 30; 20(5):408. PubMed ID: 12402348
    [Abstract] [Full Text] [Related]

  • 12. Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.
    Tse JY, Ng HK, Lo KW, Chong EY, Lam PY, Ng EK, Poon WS, Huang DP.
    Hum Pathol; 1998 Nov 30; 29(11):1200-7. PubMed ID: 9824096
    [Abstract] [Full Text] [Related]

  • 13. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
    Bièche I, Lidereau R.
    Mol Carcinog; 2000 Nov 30; 29(3):151-8. PubMed ID: 11108660
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24.
    Yamasaki H, Mizusawa N, Nagahiro S, Yamada S, Sano T, Itakura M, Yoshimoto K.
    Clin Endocrinol (Oxf); 2003 Apr 30; 58(4):464-70. PubMed ID: 12641630
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
    Burns KL, Ueki K, Jhung SL, Koh J, Louis DN.
    J Neuropathol Exp Neurol; 1998 Feb 30; 57(2):122-30. PubMed ID: 9600204
    [Abstract] [Full Text] [Related]

  • 18. Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas.
    Zhuang SM, Wiseman RW, Söderkvist P.
    Cancer Lett; 2000 May 01; 152(2):129-34. PubMed ID: 10773403
    [Abstract] [Full Text] [Related]

  • 19. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP, Burns KL, Rosenberg AE, Louis DN.
    Am J Pathol; 1998 Jul 01; 153(1):159-63. PubMed ID: 9665476
    [Abstract] [Full Text] [Related]

  • 20. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J.
    Cancer Res; 1996 Dec 01; 56(23):5475-83. PubMed ID: 8968104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.